Tentarix Biotherapeutics

Unlocking Powerful Biology

with High-Precision Biologics


Photo: Octopus Dance by Morten Brekkevold

New Website: Coming Soon

The Tentarix platform harnesses nature's diversity engine to create novel biologics. Our therapeutics have exquisite specificity and the ability to precisely target selected cell types, allowing for more potent dosing and enhanced immune cell engagement.

Management Team

Paul Grayson: President & Chief Executive Officer

Paul Grayson is a founder of Tentarix and brings over 25 years of experience from his successful career in the biotech sector. Paul specializes in start-up through IND enablement, CMC and clinical proof of concept stage products. Prior to co-founding Tentarix and becoming President and CEO, he was a Partner at Versant Ventures. During and prior to his time at Versant Ventures, Paul was President and CEO of Bird Rock Bio, a company focused on fibrotic, metabolic and inflammatory diseases. Prior to joining Bird Rock Bio, he was the founding CEO of Fate Therapeutics (NASDAQ:FATE) a clinical-stage, next-generation cellular immunotherapy company. Prior to Fate, he was managing director of Sanderling Ventures. Prior to Sanderling, he served as the founding Chairman and CEO of Senomyx (NASDAQ: SNMX).


Paul holds an MBA from the University of California, Irvine, and a B.A. in Computer Science and Biochemistry from the University of California, Los Angeles.

Stephen Demarest, PhD: Chief Scientific Officer

Stephen Demarest has 18 years of antibody and multi-specific protein development experience in both biotech and pharma. He contributed to more than 10 molecules that reached IND-enabling studies and managed departments that moved many more. Stephen's career began as a scientist at Syngenta and Diversa before moving into the role of Associate Director of Protein Sciences at Biogen Idec. Before coming to Tentarix, Stephen was the head of Lilly’s Protein Engineering and Computational Biotherapeutics Departments and a liaison to Immunology and Oncology. Stephen is a co-developer of Lilly’s OrthoMab bispecific technology with partners at UNC Chapel Hill and used the technology to bring many bispecific monoclonal antibodies into development, including with external partners. The technology has also been licensed by AbCellera. Stephen has >45 publications and is an inventor on >20 granted patents and applications.


Stephen holds a B.S. in Chemistry from Texas A&M University and a Ph.D. in Chemistry from SUNY Stony Brook. His postdoctoral studies were at The Scripps Research Institute.

Margaret Karow, PhD: Chief Development Officer

Margaret Karow is a founder at Tentarix and brings over 25 years of experience in generation and engineering of protein therapeutics. Prior to joining Tentarix, Margaret was the CSO for Gensun Biopharma, and before that she was the Senior Vice President of Pre-Clinical Development for Xilio Therapeutics (formerly Akrevia Therapeutics) where her contributions helped secure $30M Series A funding. Before joining Xilio Therapeutics, she was an Executive Director at Amgen for 10 years, and held multiple positions including leadership roles for Biosimilars Process Development, Amgen Thousand Oaks Protein Sciences, Biologics Optimization, and Site Head for Amgen Burnaby, Canada. Margaret started her career in biotech at Regeneron, over the course of a decade, had a variety of roles including Vice President and co-lead for the development of the VelocImmune mouse platform.


Margaret holds a B.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder and a Ph.D. in Biology from the University of Utah.

Alyssa Levin: Chief Financial Officer & SVP Operations

Alyssa Levin is a CPA, CA who has been involved in biotechnology finance and accounting since moving to San Diego from Vancouver, Canada in 2013. In addition to overseeing the Company's finance functions, she has helped to build the Tentarix team and San Diego facility operations since the Company's formation. Alyssa most recently held the position of CFO at Bird Rock Bio, a clinical-stage biopharmaceutical company focused on the treatment of fibrotic, metabolic and inflammatory diseases. Coinciding with her time at Bird Rock Bio, she founded a 501(c)3 non-profit initiative—the Frontline Hero Fund—which provides financial grants and counselling services to healthcare workers, first responders and their family members who have been affected by COVID-19. Alyssa started her career at the public accounting firm PwC LLP in Vancouver, Canada before moving to San Diego.


Alyssa holds a B.A. from the University of British Columbia and an M.A. in Professional Accountancy from the University of Saskatchewan.

Paul Kang: SVP Corporate Development

Paul Kang is a founder of Tentarix and has been involved in the development and application of antibody generation technologies for over 20 years, with time at ImmGenics Pharmaceuticals, Abgenix Inc., and Amgen Inc. Paul has played an instrumental role in the development and deployment of novel first-in-class antibody discovery technologies, including ImmGenics’ SLAM technology (Selected Lymphocyte Antibody Method) and Abgenix’s XenoMouse Technology, which was subsequently acquired by Amgen. At Amgen, Paul oversaw Amgen British Columbia’s Preclinical In Vitro Cellular Assay and In Vivo Pharmacology research teams, whose primary responsibilities were the screening and characterization of XenoMouse-derived antibodies. After leaving Amgen, Paul was a co-founder of Innovative Targeting Solutions (ITS). As CSO of ITS, Paul oversaw the advancement of the company’s HuTARG protein engineering platform and the company’s six pharma collaborations. Paul is also a co-founder of A2 Biotherapeutics and an inventor on over 15 pending or granted patents.


Paul holds a B.S. from Simon Fraser University.

Michael Gallo, PhD: Chief Technology Officer

Michael Gallo is a founder of Tentarix and is the current President of Innovative Targeting Solutions and, before that, was part of the original scientific team at Cell Genesys that created XenoMouse, the premier transgenic mouse technology for generating fully human antibodies. When Abgenix spun-off from Cell Genesys in 1996, Michael served on the Strategic Planning Group and Intellectual Property Group and was the Vice President of Research. Abgenix became Amgen British Columbia, and there Michael oversaw over 100 target collaborations including AstraZeneca, Pfizer, Abbot, Curagen, Millennium, and Dendreon. As the site-head for both Abgenix’s subsidiary (Abgenix Biopharma) and Amgen’s subsidiary (Amgen British Columbia) from 2001 to 2007, he led a research unit of 65 people focused on antibody generation and the development of new antibody discovery technologies. Michael is the inventor of numerous patents including the commercial antibody Vectibix.


Michael holds a Ph.D. in Medical Microbiology and Immunology from Ohio State University and completed his postdoctoral studies at Stanford University.

Press Releases

https://www.businesswire.com/news/home/20211014005033/en/Tentarix-Biotherapeutics-Emerges-with-50-Million-Series-A

Board of Directors

Srini Akkaraju, MD, PhD

Board Chairman and Managing Director at Samsara BioCapital

Srini Akkaraju is a founder of Tentarix and also serves as a Director of Seattle Genetics, Intercept Pharmaceuticals, Versartis and aTyr Pharma. Previously, he served as a director on the boards of Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma, and Amarin Corporation. Srini founded Samsara BioCapital in 2016. His vast experience in the industry includes being a general partner at Sofinnova Ventures, Managing Director of New Leaf Ventures, Managing Director of Panorama Capital, partner at J.P. Morgan and senior management at Genentech.


Srini holds a B.S. in Biochemistry and Computer Science from Rice University, and an M.D. and a Ph.D. in Immunology from Stanford University.

Jerel Davis, PhD

Managing Director, Versant Ventures

Jerel Davis is a Managing Director of Versant Ventures based in Vancouver, Canada. Since joining Versant in 2011, he has been instrumental in establishing the company’s presence in Canada and has been involved in launching and investing in a number of Versant’s portfolio companies including BlueRock (sale), Crispr (2016 IPO), Inception 4 (sale), Inception 5 (sale), Quanticel (sale), Akero (2019 IPO), Northern (sale), Turnstone, Repare (2020 IPO), Chinook, Ventus, Integral, and VenatoRx. He has focused on company creation, syndicated deals, and creative corporate transactions with multiple pharmaceutical partners including Celgene, Roche, and Bayer. Jerel was promoted to Managing Director at Versant in April 2016.


Jerel holds a B.S. in Mathematics and Biology from Pepperdine University and a PhD in Genetics from Stanford University.

Paul Grayson

President and CEO

Paul Grayson is a founder of Tentarix and brings over 25 years of experience from his successful career in the biotech sector. Paul specializes in start-up through IND enablement, CMC and clinical proof of concept stage products. Prior to co-founding Tentarix and becoming President and CEO, he was a Partner at Versant Ventures. During and prior to his time at Versant Ventures, Paul was President and CEO of Bird Rock Bio, a company focused on fibrotic, metabolic and inflammatory diseases. Prior to joining Bird Rock Bio, he was the founding CEO of Fate Therapeutics (NASDAQ:FATE) a clinical-stage, next-generation cellular immunotherapy company. Prior to Fate, he was managing director of Sanderling Ventures. Prior to Sanderling, he served as the founding Chairman and CEO of Senomyx (NASDAQ: SNMX).


Paul holds an MBA from the University of California, Irvine, and a B.A. in Computer Science and Biochemistry from the University of California, Los Angeles.

Paul Kang

Tentarix, SVP Corp Development Innovative Targeting Solutions, CSO

Paul Kang is a founder of Tentarix and has been involved in the development and application of antibody generation technologies for over 20 years, with time at ImmGenics Pharmaceuticals, Abgenix Inc., and Amgen Inc. Paul has played an instrumental role in the development and deployment of novel first-in-class antibody discovery technologies, including ImmGenics’ SLAM technology (Selected Lymphocyte Antibody Method) and Abgenix’s XenoMouse Technology, which was subsequently acquired by Amgen. At Amgen, Paul oversaw Amgen British Columbia’s Preclinical In Vitro Cellular Assay and In Vivo Pharmacology research teams, whose primary responsibilities were the screening and characterization of XenoMouse-derived antibodies. After leaving Amgen, Paul was a co-founder of Innovative Targeting Solutions (ITS). As CSO of ITS, Paul oversaw the advancement of the company’s HuTARG protein engineering platform and the company’s six pharma collaborations. Paul is also a co-founder of A2 Biotherapeutics and an inventor on over 15 pending or granted patents.


Paul holds a B.S. from Simon Fraser University.

Marcos Milla, PhD

Venture Partner, Samsara BioCapital

Marcos Milla's expertise in drug discovery spans the areas of immunology, oncology, and neuroscience. He has held industry and academic appointments at GlaxoSmithKline, Perelman School of Medicine at the University of Pennsylvania, Roche Palo Alto, Janssen Research & Development, Adaptive Biotechnologies and, most recently, as the CSO of Synthorx. At Synthorx, Marcos directed the company's research efforts to discover and develop optimized biologics for oncology indications, and helped lead Synthorx through their IPO and $2.5B acquisition by Sanofi. He previously directed efforts focused on multiple intracellular and extracellular target classes, including cell surface and nuclear receptors, ion channels, kinases and proteinases. His work led to the discovery of a break-through series of small molecule modulators of cytokine-receptor interactions. He also has experience with finding novel ways of reading pharmacological responses using high-content imaging and gene expression readouts.


He holds a B.S. in Cell Biology from Universidad Peruana Cayetano Heredia in Lima, Peru and a Ph.D. in Molecular Biology from Saint Louis University. He did his postdoctoral training at MIT and at Duke University School of Medicine.

Careers

Tentarix Biotherapeutics is an exciting company with a game-changing technology platform that allows for the discovery of next generation, multi-specific investigational drugs to address the key limitations of existing cancer, autoimmune and other disease therapies.

We are led by a seasoned executive team with proven expertise in the field of multi-specific drug discovery. We are committed to hiring and retaining highly qualified and motivated team members who are passionate about making a difference for patients in the modern drug discovery landscape with our ground-breaking technology.

Tentarix team members are creative, hands-on, self-directed, and display excellent communication skills. They also exhibit a high level of integrity, resiliency and a determination to contribute to the success of the company. We offer autonomy, flexibility, a modern culture and the best tools to ensure the success of our individuals and collectively.

Our employees are the Company’s most valuable asset, so we offer attractive compensation and benefits packages to retain the best in the field.

Stay in touch

10355 Science Center Drive, Suite 120

San Diego, CA, 92121

https://www.linkedin.com/company/tentarix-biotherapeutics

Contact:



Phone: (858) 866 - 8832

Email: info@tentarix.com